IMVT Stock Cash Flow Statements

Immunovant Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Immunovant Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

cash flows from operating activities
net income	-120,613,000	-106,449,000	-111,122,000	-109,119,000	-87,150,000	-75,319,000	-51,418,000	-58,662,000	-73,937,000	-59,432,000	-63,227,000	-47,928,000	-40,373,000	-47,171,000	-41,385,000	-37,703,000	-30,471,000	-28,158,000	-31,776,000	-20,789,000	-26,708,000	-20,551,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	18,510,000	11,687,000	11,652,000	12,693,000	13,455,000	9,679,000	10,220,000	10,529,000	10,688,000	7,546,000	8,906,000	8,157,000	7,687,000	11,863,000	10,159,000	8,361,000	3,861,000	5,488,000	5,992,000	3,361,000	3,981,000
depreciation on property and equipment	107,000	109,000	99,000	89,000	80,000	64,000	58,000	56,000	53,000	54,000	49,000	46,000	44,000	39,000	33,000	28,000	26,000	22,000	19,000	14,000	10,000
non-cash lease expense	24,000	22,000	23,000	22,000	66,000	252,000	295,000	293,000	290,000	287,000	284,000	281,000	279,000	275,000	280,000	277,000	274,000	219,000
changes in operating assets and liabilities:
accounts receivable	129,000	85,000	-197,000	417,000	2,927,000	-4,140,000	266,000	-561,000	-142,000	2,000	2,945,000	9,764,000	-947,000
prepaid expenses and other current assets	498,000	-15,210,000	-5,239,000	-4,692,000	-1,849,000	-8,518,000	2,836,000	-1,022,000	8,262,000	-6,236,000	-4,171,000	-925,000	-9,201,000	5,946,000	-7,830,000	982,000	3,039,000
other assets	-1,361,000	-195,000	530,000
accounts payable	-9,401,000	-2,304,000	-260,000	9,369,000	3,879,000	3,392,000	-3,704,000	-18,915,000	25,011,000	-12,629,000	6,472,000	6,518,000	-17,485,000	14,871,000	-427,000	1,135,000	675,000	337,000	-3,823,000	-2,074,000	6,811,000	-1,637,000
accrued expenses and other current liabilities	-5,304,000
net cash from operating activities	-117,411,000	-110,637,000	-100,391,000	-88,647,000	-76,199,000	-59,699,000	-47,098,000	-60,060,000	-47,370,000	-55,793,000	-46,395,000	-20,186,000	-65,819,000	-32,956,000	-31,895,000	-20,047,000	-21,214,000	-22,496,000	-22,815,000	-24,218,000	-13,798,000	-23,050,000
capex	0	0	-180,000	-196,000	-182,000	0	-131,000	-34,000	-45,000	0	-98,000	-31,000	-42,000	0	-74,000	-44,000	-18,000	0	-29,000	-39,000	-28,000	0
free cash flows	-117,411,000	-110,637,000	-100,571,000	-88,843,000	-76,381,000	-59,699,000	-47,229,000	-60,094,000	-47,415,000	-55,793,000	-46,493,000	-20,217,000	-65,861,000	-32,956,000	-31,969,000	-20,091,000	-21,232,000	-22,496,000	-22,844,000	-24,257,000	-13,826,000	-23,050,000
cash flows from investing activities
purchase of property and equipment			-180,000	-196,000	-182,000		-131,000	-34,000	-45,000		-98,000	-31,000	-42,000		-74,000	-44,000	-18,000		-29,000	-39,000	-47,000
net cash from investing activities		-201,000	-180,000	-196,000	-182,000	-150,000	-131,000	-34,000	-45,000	-26,000	-98,000	-31,000	-42,000	-118,000	-74,000	-44,000	-18,000	-95,000	-29,000	-39,000	-47,000	-10,000
cash flows from financing activities
proceeds from stock options exercised	2,918,000	931,000	2,464,000	730,000	686,000	1,545,000	3,111,000	148,000	890,000	233,000	403,000	0	21,000					0	725,000	119,000	63,000
net cash from financing activities	2,918,000	450,612,000	2,464,000	730,000	686,000	1,545,000	469,844,000	148,000	890,000	233,000	70,631,000	0	21,000	0	0	200,038,000	91,000	763,000	446,000	188,350,000	193,553,000	101,000
effect of exchange rate changes on cash and cash equivalents	-566,000	-488,000	-149,000	1,049,000	335,000	2,732,000	-1,606,000	-86,000	-47,000	-490,000	2,697,000
net change in cash and cash equivalents	-115,059,000	339,286,000	-98,256,000	-87,064,000	-75,360,000	-55,572,000	421,009,000	-60,032,000	-46,572,000	-56,076,000	26,835,000
cash and cash equivalents – beginning of period	713,971,000	0	0	0	635,365,000	0	0	0	376,532,000	0	0
cash and cash equivalents – end of period	598,912,000	339,286,000	-98,256,000	-87,064,000	560,005,000	-55,572,000	421,009,000	-60,032,000	329,960,000	-56,076,000	26,835,000
income tax receivable																		-67,000	-441,000	-16,000	12,000	-36,000
accrued expenses		1,647,000	4,146,000	10,668,000	-7,538,000	15,459,000	-5,343,000	8,527,000	-17,294,000	14,290,000	2,635,000	4,185,000	-5,542,000	-6,716,000	8,290,000	6,727,000	1,171,000	1,878,000	7,756,000	-4,569,000	-597,000	2,675,000
operating lease liabilities		-23,000	-23,000	-23,000	-69,000	-258,000	-308,000	-305,000	-301,000	-292,000	-288,000	-284,000	-281,000				-360,000	-111,000	-544,000	-2,000	-141,000
due to roivant sciences ltd.																						56,000
purchases of property and equipment
proceeds from issuance of common stock upon underwritten offering and private placement
payment of offering and private placement costs						0
non-cash operating activity
operating lease right-of-use assets obtained in exchange for operating lease liabilities
supplemental disclosure of cash paid:
income taxes		901,000	0															0	74,000
proceeds from issuance of common stock upon underwritten public offering and private placement
proceeds from issuance of common stock upon underwritten offering										0
payment of offering costs										0
proceeds from investment by roivant sciences ltd.														0	0
capital contributions														0	0	38,000	91,000	763,000	116,000	53,000	164,000	291,000
other non-cash items
effect of exchange rate changes on cash													-772,000	-112,000
net change in cash													-66,612,000	-33,186,000	-31,949,000	179,947,000	-21,141,000	-21,828,000	-22,398,000	164,093,000	179,708,000	-22,959,000
cash – beginning of period													493,817,000	0	0	0	400,146,000	0	0	0	100,571,000	0
cash – end of period													427,205,000	-33,186,000	-31,949,000	179,947,000	379,005,000	-21,828,000	-22,398,000	164,093,000	280,279,000	-22,959,000
preferred stock as converted													10,000,000	0	0	0	10,000,000	0	0	0	10,000,000
options													8,214,245,000		546,632,000	-555,245,000	6,712,189,000		-76,950,000	596,128,000	5,238,554,000
restricted stock units													2,731,530,000	-865,945,000	142,712,000	2,462,174,000	931,923,000		87,780,000	0	127,200,000
total													10,955,775,000	449,210,000	689,344,000	1,906,929,000	7,654,112,000	3,111,963,000	10,830,000	-10,303,872,000	16,275,754,000
proceeds from issuance of common stock upon underwritten public offering																		0	0	188,753,000	131,030,000
proceeds from issuance of common stock upon warrant redemption																		0	0	0	65,752,000
payment of deferred offering costs																		0	-261,000	-373,000	-602,000
repayment of note payable to roivant sciences ltd.																				-202,000	-2,854,000
stock options
operating lease and other noncurrent liabilities															-275,000
foreign currency translation adjustments																	571,000	-765,000	689,000	-232,000	26,000
restricted stock																					900,000,000
earnout shares																					10,000,000,000
loss on disposal of property and equipment																						0
gain on extinguishment of convertible notes
write-off of deferred offering costs																						0
prepaid expenses																		-1,339,000	-1,119,000	-41,000	-353,000	-5,415,000
value-added tax receivable																		0	0	0	3,009,000	-13,000
proceeds from notes payable to roivant sciences ltd.																						0
repayment of convertible promissory note payable to roivant sciences ltd.																						0
proceeds from convertible promissory notes
repayment of convertible promissory notes
settlement of common stock subscribed																						0
recapitalization transaction																						0
operating lease right-of-use assets obtained and exchanged for operating lease liabilities																		32,000	259,000	-291,000	4,215,000
non-cash investing activity
payable for purchase of property and equipment
non-cash financing activity
conversion of convertible promissory notes to common stock																						0
deferred offering costs in accrued expenses																						-328,000
cancellation of interest on convertible promissory notes recorded in equity
total non-cash financing activity
warrants
gain on extinguishment of convertible notes payable
income tax payable
proceeds from convertible promissory notes payable
repayment of convertible promissory notes payable
noncash lease expense																				279,000	152,000
other
proceeds from note payable to roivant sciences ltd.
purchase of property and equipment in accounts payable																					19,000
non-cash investing and financing activities
net parent investment
proceeds from issuance of common stock
non-cash investing activities
non-cash financing activities
reclassification of net parent investment to accumulated deficit
common stock issuance costs in accrued expenses
cancelation of interest on convertible promissory notes recorded in equity
•
stock-based compensation expense
depreciation expense
unrealized currency translation adjustment
purchase of property and equipment in accounts payable and amounts due to roivant sciences ltd.

We provide you with 20 years of cash flow statements for Immunovant stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Immunovant stock. Explore the full financial landscape of Immunovant stock with our expertly curated income statements.

The information provided in this report about Immunovant stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.